ARS Pharmaceuticals (NASDAQ:SPRY) Given New $27.00 Price Target at Leerink Partners

ARS Pharmaceuticals (NASDAQ:SPRY) had its price objective upped by Leerink Partners from $26.00 to $27.00 in a report released on Monday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $26.00.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY opened at $12.01 on Monday. The stock has a 50-day moving average price of $12.87 and a two-hundred day moving average price of $12.80. ARS Pharmaceuticals has a 12 month low of $5.75 and a 12 month high of $18.51.

Insider Activity at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, COO Brian Dorsey sold 25,000 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $12.30, for a total transaction of $307,500.00. Following the transaction, the chief operating officer now directly owns 6,024 shares of the company’s stock, valued at approximately $74,095.20. The trade was a 80.58 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Laura Shawver sold 50,000 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $11.10, for a total value of $555,000.00. Following the completion of the sale, the director now directly owns 210,346 shares of the company’s stock, valued at approximately $2,334,840.60. The trade was a 19.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,095,558 shares of company stock worth $16,853,686 in the last quarter. 40.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. First Turn Management LLC acquired a new stake in shares of ARS Pharmaceuticals during the third quarter worth $8,603,000. Jacobs Levy Equity Management Inc. grew its holdings in ARS Pharmaceuticals by 78.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 653,048 shares of the company’s stock worth $9,469,000 after acquiring an additional 288,021 shares during the period. Miura Global Management LLC bought a new position in shares of ARS Pharmaceuticals in the 3rd quarter worth about $3,915,000. Wexford Capital LP acquired a new position in shares of ARS Pharmaceuticals in the 3rd quarter valued at about $3,601,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of ARS Pharmaceuticals by 766.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock valued at $3,401,000 after purchasing an additional 207,456 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.